房颤患者单药、双药或三联抗栓治疗的大出血发生率
与维生素K拮抗剂单药治疗相比,三联治疗的大出血风险显著升高(VKA三联HR 3.73,DOAC三联HR 2.28)。高龄(>90岁)、CHA2DS2-VASc评分>6或既往大出血史者三联治疗出血率极高。
要点
- 三联抗栓治疗大出血风险显著高于单药或双药治疗。
- VKA三联治疗大出血风险为VKA单药的3.73倍。
- 高龄、高CHA2DS2-VASc评分或既往大出血者三联治疗需谨慎。
核心结论
- 房颤患者三联抗栓治疗的大出血发生率显著高于双药或单药治疗。
- 高龄(>90岁)、CHA2DS2-VASc评分>6或既往大出血史者接受三联治疗时出血率极高,需慎重考虑。
研究设计与样本
- 治疗信息来源于处方数据库,包括未抗凝、维生素K拮抗剂、直接口服抗凝药、血小板抑制剂及联合抗栓方案。
- 主要终点为大出血(需住院或导致死亡的出血),随访总时长1 373 131患者年。
主要发现
- 随访期间共发生31 459例大出血,总发生率为2.3/100患者年(95%CI 2.3-2.3)。
- 与VKA单药治疗相比,调整后大出血风险比:双联抗血小板治疗1.13(95%CI 1.06-1.19),VKA+抗血小板药1.82(95%CI 1.76-1.89),DOAC+抗血小板药1.28(95%CI 1.13-1.44),VKA三联治疗3.73(95%CI 3.23-4.31),DOAC三联治疗2.28(95%CI 1.67-3.12)。
- 接受三联治疗的患者大出血发生率为10.2/100患者年。
- 三联治疗中,年龄>90岁者大出血发生率为22.8/100患者年,CHA2DS2-VASc评分>6者为17.6/100患者年,有既往大出血史者为17.5/100患者年。
临床怎么用
- 对房颤患者应避免不必要的三联抗栓治疗,优先考虑双药或单药方案。
- 高龄(>90岁)、CHA2DS2-VASc评分>6或既往大出血史者,处方三联治疗前需仔细评估出血风险。
局限性
- 观察性设计可能残留混杂因素。
- 治疗信息来自处方数据库,可能存在用药依从性偏差。
- 大出血定义限于需住院或致死性出血,可能低估临床相关出血。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with atrial fibrillation generally require anticoagulant therapy and, at times, therapy with additional platelet aggregation inhibitors. Data are scarce on bleeding rates in high-risk groups receiving combination therapy, such as the elderly or patients with a high CHA2DS2-VASc score. METHODS: We conducted a nationwide cohort study of Danish patients with atrial fibrillation ≥50 years of age. Treatments were ascertained from a prescription database. These included no anticoagulant treatment, and treatment with vitamin K antagonists, direct oral anticoagulants, platelet inhibitors, and combinations of antithrombotic drugs. Incidence rates (IRs) of major bleeding and hazard ratios were estimated overall, and also stratified by treatment modality, age, CHA2DS2-VASc score, and comorbidity. Major bleeding was defined as bleeding requiring hospitalization or causing death. RESULTS: We identified 272 315 patients with atrial fibrillation. Median age was 75 years (interquartile range, 67-83) and 47% were women. Over a total follow-up period of 1 373 131 patient-years (PYs), 31 459 major bleeds occurred (IR 2.3/100 PYs; 95% CI, 2.3-2.3/100 PYs). In comparison with vitamin K antagonist monotherapy, adjusted hazard ratios of major bleeding were 1.13 (95% CI, 1.06-1.19) for dual antiplatelet therapy, 1.82 (95% CI, 1.76-1.89) for therapy with a vitamin K antagonist and an antiplatelet drug, 1.28 (95% CI, 1.13-1.44) for therapy of a direct oral anticoagulant with an antiplatelet drug, 3.73 (95% CI, 3.23-4.31) for vitamin K antagonist triple therapy, and 2.28 (95% CI, 1.67-3.12) for direct oral anticoagulant triple therapy. Subgroup analyses showed similar patterns. The IR for major bleeding was 10.2/100 PYs among patients receiving triple therapy. Very high major bleeding rates occurred among patients on triple therapy aged >90 years (IR 22.8/100 PYs) or with a CHA2DS2-VASc score >6 (IR 17.6/100 PYs) or with a history of major bleeding (IR 17.5/100 PYs). CONCLUSIONS: Patients with atrial fibrillation on triple therapy experienced high rates of major bleeding in comparison with patients on dual therapy or monotherapy. The high bleeding rates observed in patients on triple therapy >90 years of age or with a CHA2DS2-VASc score >6 or with a history of a major bleeding warrants careful consideration of such therapy in these patients.
引用
- van Rein N, Heide-Jørgensen U, Lijfering WM, et al. Major Bleeding Rates in Atrial Fibrillation Patients on Single, Dual, or Triple Antithrombotic Therapy. Circulation. 2019. PMID: 30586754. doi:10.1161/CIRCULATIONAHA.118.036248
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。